4D Molecular Therapeutics, Inc. short interest in 2026
In 2026, 4D Molecular Therapeutics, Inc.'s disclosed short interest ran from 14.01% of shares outstanding on 15 Jan 2026 to 16.64% on 15 Sep 2026, a change of +2.63 percentage points. The year's high was 19.22% on 30 Jun 2026 and its low 13.72% on 30 Jan 2026, averaging 16.48% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.32 days on 14 Aug 2026. Full history: 4D Molecular Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 14.01% (15 Jan 2026)
- End of year
- 16.64% (15 Sep 2026)
- Change
- +2.63 pp
- High
- 19.22% (30 Jun 2026)
- Low
- 13.72% (30 Jan 2026)
- Average
- 16.48%
- Highest days to cover
- 22.32 (14 Aug 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 14.01% | 11.22 | results (8-K) |
| 30 Jan 2026 | 13.72% | 13.28 | |
| 13 Feb 2026 | 14.37% | 13.01 | |
| 27 Feb 2026 | 14.98% | 15.11 | |
| 13 Mar 2026 | 15.37% | 14.13 | |
| 31 Mar 2026 | 15.98% | 12.12 | 10-K filed, results (8-K) |
| 15 Apr 2026 | 16.94% | 16.29 | |
| 30 Apr 2026 | 17.64% | 17.90 | |
| 15 May 2026 | 17.46% | 19.08 | 10-Q filed, results (8-K) |
| 29 May 2026 | 17.62% | 13.97 | |
| 15 Jun 2026 | 18.68% | 16.53 | |
| 30 Jun 2026 | 19.22% | 9.10 | |
| 15 Jul 2026 | 16.42% | 15.51 | |
| 31 Jul 2026 | 17.39% | 17.69 | |
| 14 Aug 2026 | 17.03% | 22.32 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 16.72% | 8.15 | |
| 15 Sep 2026 | 16.64% | 18.55 |
See also: 4D Molecular Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.